These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27085530)

  • 1. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
    Jiang Q; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
    Wang HF; Zhang YL; Liu XL; Zhu HL; Liang R; Liu BC; Zhou L; Meng L; Li WM; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):535-542. PubMed ID: 34455739
    [No Abstract]   [Full Text] [Related]  

  • 5. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients'perspective].
    Jiang Q; Liu ZC; Zhang SX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):559-64. PubMed ID: 27535854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.
    Jiang Q; Wang H; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2619-2630. PubMed ID: 28894944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
    Yu L; Wang HB; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):929-935. PubMed ID: 27995875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
    Yu L; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
    [No Abstract]   [Full Text] [Related]  

  • 12. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    Curr Med Res Opin; 2014 Jul; 30(7):1345-52. PubMed ID: 24640967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center].
    Yu L; Qin YZ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):754-760. PubMed ID: 29081191
    [No Abstract]   [Full Text] [Related]  

  • 18. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
    Machado-Alba JE; Machado-Duque ME
    Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
    Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.